Effect of chemotherapy on the expression of CD8+CD28-T cells in peripheral blood of nonsmallcell lung cancer patients

doi:10.3760/cma.j.issn.1673-422X.2016.05.004

Abstract

Abstract: ObjectiveTo observe the expression of CD8＋CD28-T cells in the peripheral blood of nonsmallcell lung cancer (NSCLC) patients, and to investigate the effect of chemotherapy on CD8＋CD28-T cells expression and its clinical significance. MethodsFlow cytometry was used to evaluate the level of CD8＋CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls. The association between CD8＋CD28-T cells and the clinical features was analyzed. We also investigated the changes of CD8＋CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine, cisplatin) and NP (navelbine, cisplatin). ResultsThe proportion of CD8＋CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003%±15.329% vs. 41.036%±15.435%, t=35.904, P=0.001). No correlation was found between CD8＋CD28-T cells expression and the gender (F=1.374, P=0.697), pathological pattern (F=0.779, P=0.509) and clinical stage (F=0.070, P=0.933). But CD8＋CD28-T cells expression was correlated with the age (F=15.038, P=0.001). The level of CD8＋CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293%±14.637% vs. 58.793%±12.510%, t=2.017, P=0.044). And the level of CD8＋CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127%±13.924% vs. 60.700%±16.401%, t=3.007, P=0.009). ConclusionCD8＋CD28-T cells express highly in NSCLC patients peripheral blood. Chemotherapy downregulates CD8＋CD28-T cells expression, which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients.

Key words: Carcinoma, nonsmallcell lung, Drug therapy, CD8positive Tlymphocytes

Liang Guanzhong, Wang Yanfeng, Han Fucai. Effect of chemotherapy on the expression of CD8+CD28-T cells in peripheral blood of nonsmallcell lung cancer patients[J]. Journal of International Oncology, 2016, 43(5): 335-339.

References

［1］ Wang HY, Wang RF. Regulatory T cells and cancer［J］. Curr Opin Immunol, 2007, 19(2): 217-223. ［2］曹雪涛. 免疫学前沿进展［M］ . 北京: 人民卫生出版社, 2009: 365-387. ［3］ Liu Z, Tugulea S, Cortesini R, et al. Specific suppression of T helper alloreactivity by alloMHC class Ⅰrestricted CD8+CD28-T cells［J］. Int Immunol, 1998, 10(6): 775-783. ［4］ Yan X, Zhao X, Jiao S, et al. Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2012, 15(3): 164-171. DOI: 10.3779/j.issn.10093419.2012.03.06. ［5］ Riha P, Rudd CE. CD28 cosignaling in the adaptive immune response［J］. Self Nonself, 2010, 1(3): 231-240. DOI: 10.4161/self.1.3.12968. ［6］ Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers［J］. J Immunol, 2007, 179(7): 4323-4334. ［7］ Batliwalla FM, Rufer N, Lansdorp PM, et al. Oligoclonal expansions in the CD8(+)CD28(－) T cells largely explain the shorter telomeres detected in this subset: analysis by flow FISH［J］. Hum Immunol, 2000, 61(10): 951-958. ［8］ Li J, Liu Z, Jiang S, et al. T suppressor lymphocytes inhibit NFkappa Bmediated transcription of CD86 gene in APC［J］. J Immunol, 1999, 163(12): 6386-6392. ［9］ Karagz B, Bilgi O, Gümüs M, et al. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients［J］. Med Oncol, 2010, 27(1): 29-33. DOI: 10.1007/s1203200891659. ［10］ Meloni F, Morosini M, Solari N, et al. Foxp3 expressing CD4+CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma［J］. Hum Immunol, 2006, 67(1/2): 1-12. DOI: 10.1016/j.humimm.2005.11.005. ［11］ Filaci G, SuciuFoca N. CD8+ T suppressor cells are back to the game: are they players in autoimmunity?［J］. Autoimmun Rev, 2002, 1(5): 279283. ［12］ Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation［J］. J Clin Invest, 2004, 114(9): 1198-1208. DOI: 10.1172/JCI23411. ［13］ Chen X, Priatel JJ, Chow MT, et al. Preferential development of CD4 and CD8 T regulatory cells in RasGRP1deficient mice［J］. J Immunol, 2008, 180(9): 5973-5982. ［14］薛利军, 尹路, 陈春球, 等. 利用RNA干扰诱导产生的CD8+CD28-抑制性T淋巴细胞的免疫学特性［J］. 中华器官移植杂志, 2009, 30(5): 295-299. DOI: 10.3760/cma.j.issn.02541785.2009.05.012. ［15］储以微, 刘荣军, 张镭, 等. 肺癌患者化疗前后免疫细胞格局的改变及其临床意义［J］. 中国肿瘤生物治疗杂志, 2006, 13(4): 253-256. DOI: 10.3872/j.issn.1007385X.2006.04.004. ［16］ Wang LX, Li R, Yang G, et al. Interleukin7dependent expansion and persistence of melanomaspecific T cells in lymphodepleted mice lead to tumor regression and editing［J］. Cancer Res, 2005, 65(22): 10569-10577. DOI: 10.1158/00085472.CAN052117. ［17］ Zhang TQ, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer［J］. Cancer Immunol Immunother, 2009, 58(4): 475-492. DOI: 10.1007/s002620080598y. ［18］ Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients［J］. Cancer Immunol Immunother, 2007, 56(5): 641-648. DOI: 10.1007/s0026200602258. ［19］ Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine［J］. Blood, 2005, 106(6): 2018-2025. DOI: 10.1182/blood2005020642. ［20］ Liu Q, Zheng H, Chen X, et al. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(－) regulatory T cells［J］. Cell Mol Immunol, 2015, 12(6): 708-718. DOI: 10.1038/cmi.2014.118.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[4]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[7]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[8]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[9]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[10]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng. Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(11): 665-670.
[11]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[12]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer [J]. Journal of International Oncology, 2021, 48(5): 302-307.
[13]	Song Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying. Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(3): 156-163.
[14]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng. Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(12): 755-759.
[15]	Wang Xuan, Cui Lichun, Dang Shengqiang. Effects of apatinib combined with chemoradiotherapy on the efficacy and tumor markers of advanced gastric cancer [J]. Journal of International Oncology, 2021, 48(10): 602-607.